Clinical trials: Skin Tumors
Melanoma
Study of HL-085 in NRAS Mutant Advanced Melanoma
This is a phase I/II, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetics and efficacy in patients with NRAS mutant advanced melanoma .
- Trial name
- NCT03973151
- Testing
- HL-085
- Where
- 2 sites in China
- Volunteers
- 42 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Breast Neoplasms, Neoplasms
A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with advanced breast cancer.
- Conditions
- Breast Neoplasms, Neoplasms, Neoplasms by Site, Breast Diseases
- Trial name
- NCT00050427
- Testing
- ET743
- Volunteers
- 53 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Melanoma, Solid Tumors
A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)
This is a 5-part dose-finding and preliminary efficacy study of pembrolizumab (Pembro) + dabrafenib (D) + trametinib (T) for participants with advanced melanoma and solid tumors.
- Trial name
- NCT02130466
- Testing
- Pembrolizumab, Dabrafenib, Trametinib
- Volunteers
- 184 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Neoplasms
Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients
The primary objective of this study is to assess the pathological Complete Response (pCR) rate by treatment arm (according to Chevallier criteria).
- Trial name
- SATIN (NCT00485979)
- Testing
- larotaxel (XRP9881), docetaxel, trastuzumab
- Where
- 8 sites in Belgium, Brazil and 6 more
- Volunteers
- 330 people
- Sponsor
- Sanofi
Breast Cancer
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
The purpose of this study is to provide eribulin to patients with advanced breast cancer who have no other treatment options and therapy is requested by an Investigator.
- Trial name
- NCT01142661
- Testing
- Eribulin Mesylate
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Eisai Inc.
Malignant Melanoma
IMCgp100-401 Rollover Study
IMCgp100-401 is a rollover study that is designed to provide continued access to IMCgp100 for eligible participants with advanced melanoma who have previously participated in an IMCgp100 study (parent study).
- Trial name
- NCT02889861
- Testing
- IMCgp100
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Immunocore Ltd
Atopic Dermatitis, Pediatric ALL
TRacking Atopic Dermatitis Infants and Their Microbiome (TRAM)
TRacking Atopic dermatitis Infants and their Microbiome: A study to primarily assess the user experience of parents of infants with early onset eczema and parents of healthy infants on OneBiome real-world evidence research…
- Trial name
- TRAM (NCT06578351)
- Where
- Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Danone Asia Pacific Holdings Pte, Ltd.
Dupuytren's Contracture
Post Approval Commitment Study
An agreement has been made to conduct a post-approval commitment study that provides supplementary information relating to the use of Xiapex® as well as other non-pharmacological treatments for Dupuytren's contracture by health…
- Trial name
- NCT01444729
- Testing
- Xiapex, surgery
- Where
- 7 sites in Norway, Spain
- Volunteers
- 305 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Actinic Keratosis
5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis
The KOHDIAK study is a prospective, three-armed, randomised, double-blind study to evaluate the efficacy and safety of the treatment of mild and moderate actinic keratosis with a 5% potassium hydroxide solution (Solcera, medical…
- Trial name
- KOHDIAK (NCT04552327)
- Testing
- Solcera, Solaraze
- Where
- 18 sites in Germany
- Volunteers
- 631 people
- Sponsor
- Infectopharm Arzneimittel GmbH
Breast Cancer
Open Label Immunotherapy Trial for Breast Cancer
This Phase II will evaluate a new type of breast cancer immunotherapy based on a fundamentally new approach that has been successfully tested in a published clinical study of liver cancer.
- Trial name
- V3-MOMMO (NCT03572361)
- Testing
- V3-MOMMO
- Where
- Mongolia
- Volunteers
- 20 people
- Sponsor
- Immunitor LLC
Breast Cancer
LightPathTM Imaging System for Ex-vivo Assessment of Margin and Lymph Node Status in Breast Cancer Surgical Specimens
This study is a prospective, cross-sectional observational single centre study to assess the feasibility of intra-operative Cerenkov Luminescence Imaging (CLI) of breast cancer wide local excision (WLE) specimens and dissected…
- Trial name
- NCT02037269
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Lightpoint Medical Limited
Melanoma
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
The purpose of this study is to determine the maximum tolerated dose and characterize the safety profile of durvalumab (MEDI4736) in combination with dabrafenib and trametinib or with trametinib alone in participants with…
- Trial name
- NCT02027961
- Testing
- Durvalumab, Dabrafenib, Trametinib
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 68 people
- Sponsor
- MedImmune LLC
Metastatic Breast Cancer
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
This is a multicenter, open-label, single-arm Phase II study designed to evaluate the effect of T-DM1 on the duration of corrected QT (QTc) interval in patients with HER2-positive locally advanced or metastatic breast cancer and…
- Trial name
- NCT00943670
- Testing
- pertuzumab, Trastuzumab emtansine [Kadcyla]
- Volunteers
- 51 people
- Sponsor
- Genentech, Inc.
Breast Cancer, Ovarian Cancer
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
This is a Phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of PF-07224826, as a single agent or in…
- Conditions
- Breast Cancer, Ovarian Cancer, Liposarcoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT05905341
- Testing
- PF-07224826, Fulvestrant
- Sponsor
- Pfizer
Breast Cancer Detection, Dense Breast Parenchyma
Delphinus SoftVue™ ROC Reader Study
The purpose of this multi-reader, multi-case (MRMC) reader study is to evaluate reader performance when SoftVue™ automated breast ultrasound and screening mammography are combined, compared to screening mammography alone, in…
- Conditions
- Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening
- Trial name
- DMT SV RRS2 (NCT03972605)
- Testing
- Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Delphinus Medical Technologies, Inc.
Melanoma, Malignant Melanoma
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
This study will evaluate the efficacy and safety of T3011 in combination with Cobimetinib in patients with advanced melanoma.
- Trial name
- NCT05756556
- Testing
- T3011 + Cobimetinib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- ImmVira Pharma Co. Ltd
Rheumatoid Arthritis
An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis
This observational study will evaluate the effect on disease activity and the safety in routine clinical practice of MabThera (rituximab) in participants with active seropositive rheumatoid arthritis, who have an inadequate…
- Trial name
- NCT01613027
- Testing
- Rituximab
- Where
- 14 sites in Greece
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasm
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
The intravenously administered taxane, paclitaxel, is one of the most commonly employed agents for the treatment of both localized and advanced breast cancer.
- Trial name
- NCT01221870
- Testing
- Tesetaxel once every 3 weeks, Tesetaxel once weekly
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Genta Incorporated
Psoriasis Vulgaris, Psoriasis
Tofacitinib Ointment For Chronic Plaque Psoriasis
The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested.
- Trial name
- NCT01831466
- Testing
- tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g
- Where
- 54 sites in United States, Canada and 2 more
- Volunteers
- 476 people
- Sponsor
- Pfizer
Breast Cancer
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
This study is a randomised, open-label, multicentre phase III clinical study evaluating the efficacy and safety of JS105 combined with Dalpiciclib and Fulvestrant compared with Dalpiciclib and Fulvestrant in patients with…
- Trial name
- NCT07207070
- Testing
- JS105, Dalpiciclib, Fulvestrant 50 Mg/mL Intramuscular Solution
- Where
- 2 sites in China
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.